Review on t(8;16)(p11;p13) KAT6A/CREBBP, with data on clinics, and the genes implicated.
Phenotype/cell stem origin AML with t(8;16) may arise from an early stem cell with myeloid and monoblastic differentiation potential.
Epidemiology
Rare disease: a hundred and twenty cases have been reported in Mitelman database; (<1% of AML); found in children (median age at diagnosis: 1.2 years) and adults (median age at diagnosis: 59.4 years) with a female predominance (2/3).
Clinics
Disseminated intra vascular coagulation may be present; extramedullary infiltration; 20% of the cases could be therapy-related.
Cytology
Blast cells present a myelomonocytic stage of differentiation, and are characterized by a phenomenon of erythrophagocytosis with strong peroxidase and esterase activities. Immunophenotyping reveals CD4, CD14, CD13, CD33, CD56 and HLA-DR positives; CD34, CD117 and CD133 negatives. 
Prognosis
The prognosis is poor. In published series, death of patients occurs in half of the cases during the first 10 months after diagnosis due to infections or bleeding; survival is often less than 1 year but spontaneous remission has occurred (at least) once.
Cytogenetics

Additional anomalies
Sole anomaly in 53.3% of cases; in 23.3% of cases, single additional abnormality: +8 ,various; in 23.3% of cases: complex karyotype; rare chromosome 7 abnormalities, often in t-AML.
Variants
Complex variant t(8;16;V) may occur and has been described on rare occasions. 8p11 may have other partners: t(8;22)(p11;q13) which involve EP300 in 22q13, EP300 is a homologue of CREBBP with acetyltransferase activity; t(8;19)(p11;q13.3) which should involve LEUTX on 19q13 (found in one t-AML case); inv(8)(p11p13) which leads to MYST3-NCOA2 fusion; t(8;20)(p11;q13) leading to MYST3-NCOA3 fusion. 
Genes involved and proteins
KAT6A
Result of the chromosomal anomaly
Hybrid gene
Description 5' KAT6A -3' CREBBP or 5' CREBBP -3' KAT6A. 
